Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bioventus (BVS) Research & Development (2020 - 2026)

Bioventus filings provide 6 years of Research & Development readings, the most recent being $3.0 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 8.07% to $3.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.1 million, a 13.17% decrease, with the full-year FY2025 number at $12.1 million, down 13.17% from a year prior.
  • Research & Development hit $3.0 million in Q4 2025 for Bioventus, up from $2.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $7.1 million in Q4 2021 to a low of $947000.0 in Q2 2021.
  • Median Research & Development over the past 5 years was $3.6 million (2023), compared with a mean of $4.1 million.
  • Biggest five-year swings in Research & Development: plummeted 55.87% in 2021 and later surged 631.57% in 2022.
  • Bioventus' Research & Development stood at $7.1 million in 2021, then decreased by 16.29% to $5.9 million in 2022, then tumbled by 45.14% to $3.3 million in 2023, then grew by 0.28% to $3.3 million in 2024, then fell by 8.07% to $3.0 million in 2025.
  • The last three reported values for Research & Development were $3.0 million (Q4 2025), $2.9 million (Q3 2025), and $3.2 million (Q2 2025) per Business Quant data.